Systemic anaplastic large cell lymphoma (sALCL) belongs to the group of peripheral T-cell lymphomas (PTCLs) characterized by strong and universal expression of CD30.1 It is classified into anaplastic lymphoma kinase (ALK)-negative or -positive subtypes based on the expression of ALK protein.1 Until recently, the standard frontline therapy for sALCL remains CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)- based regimens, which has high rates of disease relapse despite the modest improvement in survival outcomes, particularly among ALK-negative patients.1 With the advent of the novel regimen BV-CHP (brentuximab vedotin, cyclophosphamide, doxorubicin, prednisolone), the survival outcomes of sALCL patients have improved significantly. As such, international oncology guidelines, such as the National Comprehensive Cancer Network (NCCN), recommend the BV-CHP regimen to replace the CHOP-based treatments as a new standard frontline therapy for sALCL.2 In an interview with Omnihealth Practice, Dr. Kong, Shun-Yin Jacky presented a case to demonstrate the effectiveness and safety of BV-CHP in local clinical settings and discussed the positive impact of BV-CHP on the overall sALCL management.
